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E-mail address: sven.meuth@ukmuenster.de (S.G.Multiple sclerosis (MS) is a chronic inﬂammatory disease of the central nervous system character-
ized by widespread inﬂammation, focal demyelination and a variable degree of axonal and neuronal
loss. Ionic conductances regulate T cell activation as well as neuronal function and thus have been
found to play a crucial role in MS pathogenesis. Since present therapeutical approaches are only par-
tially effective so far, ion channel modulation as a future strategy was brought into focus. Here, we
review the status quo concerning recent ﬁndings from ion channel research in MS and its animal
model, experimental autoimmune encephalomyelitis.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction reasonable to ask: Does MS belong to the group of channelopa-Multiple sclerosis (MS) is a neuroinﬂammatory disease associ-
ated with demyelination and neuronal cell death. As MS is the ma-
jor cause of neurological disability in young adults, many costs and
research efforts have been spent to identify potential therapeutic
targets. However, MS therapy is only partially effective so far.
Available drugs serve to suppress and modulate the immune re-
sponse, but their impact on disease progression and permanent
disability is only modest [1]. Accumulating neurological deﬁcits
are due to axonal and neuronal degeneration during the disease
course. Several causes are under discussion: (1) during phases of
acute inﬂammation, neuronal and axonal damage are caused by
inﬁltrating immune cells that induce either direct cell–cell-interac-
tions or transmitter release (NO, glutamate); (2) damaged oligo-
dendrocytes lead to demyelination which in turn causes an
insufﬁcient trophic supply that ﬁnally results in axonal degenera-
tion; (3) demyelination induces alterations in distribution and
expression of different ion channels and transporters in axonal
membranes. Accordingly, increased electrical activity as well as
augmented intracellular Ca2+ levels result in a dysfunction of
mitochondria and neuronal cell death in the end. Thus, it seemscal Societies. Published by Elsevier
gy – Inﬂammatory Disorders
itute of Physiology – Neuro-
3, 48149 Münster, Germany.
Meuth).thies? Originally, MS was conceived as a chronic inﬂammatory
autoimmune disease of the central nervous system which is
accompanied by demyelination that either delays or blocks electri-
cal impulse conductance in central neurons. However, the charac-
teristic accumulation of neurological deﬁcits during MS disease
course cannot solely be explained by de- and remyelination pro-
cesses. Currently, it is considered to be due to axonal and neuronal
degeneration. In this context, it can be assumed that one leading
mechanism is the reorganization and altered gene expression of
different ion channels which occurs in demyelinated axons. There-
fore, MS may be deﬁned as a member of the group of channelopa-
thies, i.e., disorders in which abnormal ion channel function leads
to the appearance of clinical signs and symptoms. These diseases
can be further subdivided in genetic, autoimmune and transcrip-
tional/translational channelopathies. (1) Genetic channelopathies
are characterized by altered ion channel structures and function
that are due to mutations in the channel genes [2]. (2) The autoim-
mune channelopathies are a group of neurological disorders in
which the patient develops raised serum levels of highly speciﬁc
autoantibodies to various neuronal or muscle ligand-gated or volt-
age-gated ion channels, or to related functional proteins [3]. (3)
The third group is comprised of translational/transcriptional chan-
nelopathies which are disorders that are caused by a dysregulated
production of normal channel proteins as a result of changes in the
complex and highly dynamic process of gene transcription [4]. As a
consequence, neuronal cell functions are perturbed. In terms of MSB.V. Open access under CC BY-NC-ND license.
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tis (EAE), a number of different reports reveal their afﬁliation to
the third subgroup of translational channelopathies in which it is
shown that the pharmacological modulation of ion channel func-
tions ameliorates disease course and clinical severity.
Studies on EAE revealed ion channels as being key players in
pathophysiological processes of MS. Ion channels on neurons but
also on immune cells strongly inﬂuence basic cellular parameters
like the membrane potential and calcium signaling, and hence they
regulate cell activity. According to their ubiquitous expression pat-
tern, ion channels have the potential to inﬂuence nearly every
stage of MS pathogenesis. The regulation of the immune response
is fundamentally dependent on ion channels which are expressed
on immune cells and which allow peripheral T lymphocytes to pro-
liferate and to produce inﬂammatory cytokines [5]. Ion channels on
neurons and glia cells affect the mechanisms that induce axonal
and neuronal degeneration in white matter of the brain and spinal
cord [6,7]. The application of different sodium, potassium and cal-
cium channel inhibitors considerably ameliorates the EAE disease
course as well as clinical severity, and it postpones the disease on-
set after immunization in comparison to sham-treated control ani-
mals [5,8,9]. Based on these results, ion channels seem to be
promising in terms of therapeutic target structures. Nevertheless,
the beneﬁcial effect in these pre-clinical blocker studies may be
mediated by two distinct pathways: either the activation/inhibi-
tion of an ion channel on nerve cells or T cells may facilitate neu-
ronal survival or mediate an immune-modulatory effect. Thus,
there is still a question to be resolved: Does a particular ion chan-
nel modulation strategy exert an immune-modulatory or a neuro-
protective effect in MS?
2. Ion channels on T lymphocytes
A major contribution of human T lymphocytes to autoimmune
inﬂammation in MS pathogenesis has already been suggested.
However, the underlying pathophysiological processes are poorly
understood. As basic cellular T cell functions like maintenance
and modulation of the membrane potential depend on a number
of different ion currents, ion channels were appraised as potential
target structures for future pharmacological approaches. After anti-
gen-speciﬁc T cell activation, a long-lasting increase in intracellular
Ca2+ levels is needed to induce gene expression, proliferation and
cytokine production. This inﬂux of cations is outbalanced by hyper-
polarizing potassium currents that preserve the driving force and a
stable membrane potential. The great importance of ionic currents
in regulating T cell effector functions is underlined by the fact that T
cell activation leads to an upregulation of a number of different ion
channel genes. After chronic stimulation, human cytotoxic CD8+ T
cells showed a close to 10-fold upregulation of mRNA coding for a
member of the two-pore domain K+ channel (K2P) family [10].
2.1. K+ channels
By now, a number of different ion channels on T cells are identi-
ﬁed. There are three most prominent potassium channels: a volt-
age-gated K+ channel [KV1.3] [11,12], a Ca2+-activated and
intermediate conductance K+ channel [KCa3.1 or IKCa] [13,14] aswell
as four distinct members of the two-pore K+ channel family: TASK1,
TASK2, TASK3 and TRESK [5,10,15,16]. In T cells under basal condi-
tions, the resting membrane potential is maintained at about
50 mV by a K+ outward current carried by Kv1.3 channels. There
are numerous studies showing that inhibition of Kv1.3 offers a
promising approach to modulate pathological immune responses
mediated by autoreactive effector memory T cells (TEM). Selective
KV1.3 inhibitors do not prevent immunological synapse formation,
but they suppress Ca2+ signaling, cytokine production andproliferation of autoantigen-speciﬁc TEM at pharmacologically rele-
vant concentrations while sparing other classes of T cells [17,18].
Although there was an apparent lack of immune system defects
due to counterbalancing chloride currents in KV1.3 knockout mice
[19], selective blockade of KV1.3 channels in miniature swines re-
duced the immune response in vivo [20]. Kv1.3 expression was
found to be high in T cell clones of the appropriate antigen speciﬁc-
ity of MS patients [21]. In addition, Kv1.3 positive cells were highly
evident in the immune inﬁltrates of themajority ofMS plaques [22].
A second type of K+ current in T cells is carried by Ca2+-activated
and intermediate conductance K+ channels (KCa3.1). Based on their
K+ conductance in the range of 20–40 pS, they can be distinguished
from the closely related small (KCa2.x; 5–20 pS) and large conduc-
tance (KCa1.1; 200–250 pS) K+ channels [23]. KCa3.1 channels are
closed under resting conditions with low basal cytosolic Ca2+ levels
and open rapidly if Ca2+ rises intracellularly. Thus, these channels
support the maintenance of the membrane potential that allows
the long-lasting Ca2+ inﬂux after T cell receptor stimulation. Blocker
studies with a highly speciﬁc blocker of these K+ channels (TRAM-
34) showed that KCa3.1 channels play a critical role in the immune
response during the development of MOG-induced EAE in C57BL/6
mice. However, the effect of TRAM-34 applicationwas reversible, as
indicated by the development of clinical EAE symptomswithin 48 h
after withdrawal of treatment [9]. Additionally, the efﬁcacy of K+
channel blockers was assessed in rats by transferring donor lym-
phocytes from rats with EAE to healthy, untreated recipients [adop-
tive transfer (AT)-EAE] [25]. Speciﬁc and simultaneous inhibition of
Kv1.3 and KCa3.1 channels by a Kv1.3 blocker (ShK) or by a combina-
tion of a highly speciﬁc Shk analogue (ShK-Dap22) plus TRAM-34
prevented lethal AT-EAE. Blockade of Kv1.3 alone with ShK-
Dap22, but not of KCa3.1 with TRAM-34, was also effective. When
administered after the onset of symptoms, ShK or the combination
of ShK-Dap22 plus TRAM-34 greatly ameliorated the clinical course
of both moderate and severe AT-EAE [24].
In human and murine T lymphocytes, three distinct members of
the two-pore potassium channel family are constitutively ex-
pressed: TASK1, TASK2 and TASK3. In addition, the expression of
the calcineurin-regulated K2P channel TRESK was postulated in leu-
kemic Jurkat T cells [16]. The functional role of TRESK in primary T
cells still needs to be conﬁrmed. However, pharmacological inhibi-
tion of TASK1, TASK2 or TASK3 leads to a reduction in cytokine pro-
duction and proliferation after T cell receptor stimulation. In vivo
relevance of T cells can be tested by AT-EAE. Pharmacological
blockade of TASK channels on myelin basic protein (MBP)-speciﬁc
T cells before transfer resulted in a signiﬁcant amelioration of the
disease course [15]. After induction of myelin oligodendrocyte gly-
coprotein (MOG)-EAE, TASK1 knockout mice showed a signiﬁ-
cantly reduced clinical severity and markedly reduced axonal
degeneration compared to control animals. Stimulated T cells from
TASK1 knockout animals showed impaired cell proliferation and
cytokine production, while the immune repertoire and naïve T cells
were otherwise normal. Supportingly, pharmacological inhibition
by the endocannabinoid anandamide (a semi-selective inhibitor
of TASK channels) reduced IFNc secretion in stimulated T cells
from wild-type but not from TASK1 knockout animals. Addition-
ally, application of anandamide protected EAE animals from severe
brain damage which was assessed by MRI [5]. Electrophysiological
data revealed a signiﬁcant contribution of TASK channels to the to-
tal outward current of T cells [15].
2.2. Calcium-release activated calcium channels, CRAC
The prolonged Ca2+ inﬂux, which is obligatory for the induction
of gene expression after antigen-speciﬁc stimulation, is mainly
generated by Ca2+-release activated Ca2+(CRAC) channels [26,27].
In lymphocytes, CRAC channels are physiologically triggered by
Table 1
Overview of ion channels expressed on T cells. The table comprises channels which are shown to be expressed in primary T cells. Signs: (+? +), unaltered gene expression;
(+? ++), upregulated gene expression; (+? +++), strongly upregulated gene expression; (+?   ), downregulated gene expression. Abbreviations: ASSC, amiloride-sensitive
sodium channel; CRAC, Ca2+-release activated Ca2+ current; IFNc, interferon-gamma; IL, interleukin; KCa, calcium-activated potassium channel; KV, voltage-gated potassium
channel; LT, lymphotoxin; MIC, Mg2+-inhibited Ca2+-permeable current; stim, stimulated; unstim; unstimulated; TASK, TWIK-related acid-sensitive K+ channel; TCM, central
memory T cell; TEM, effector memory T cell; TNFa, tumor necrosis factor-alpha; Treg, regulatory T cell; TRPM7, a member of the transient receptor potential melastatin-like (TRPM)
ion channel subfamily; VRAC, volume-regulated anion current.
Ion selectivity Channel name Human gene name Expression (unstim? stim) Remarks, effects References
K+ TASK1, K2P3.1 KCNK3 T cells  Proliferation
 IFNc, IL-2, IL-4, IL-5 and IL-10 production
 T cell invasiveness
 Axonal degeneration
[5,15]
TASK2, K2P5.1 KCNK5 CD4+cells (+? +++)  Proliferation
 IFNc production
[10]
CD8+cells (+? +++)
TASK3, K2P9.1 KCNK9 T cells  Proliferation
 IFNc and IL-2 production
[15]
KV1.1 KCNA1 CD4CD8 cells  In mouse T cells
 Thymocyte development
[33,34]
CD4+ cells (+?   )
TEM
KV1.2 KCNA2 CD4+cells (+?   )  In mouse T cells [33]
KV1.3 KCNA3 Naïve CD4+ cells (+? +)  Proliferation
 Immunological Synapse
 IL-2, TNF production
[11,21,22,35–39]
Naïve CD8+ cells (+? +)
Treg
CD4+/CD8+ TCM (+? +)
CD4+/CD8+ TEM (+? +++)
KV1.6 KCNA6 CD4+ cells (+?   )  In mouse T cells [33]
KCa3.1 KCNN4 Naïve CD4+ (+? +++)  IFNc, TNFa, IL-1, LT production
 Proliferation
[9,14,21,37,40–43]
Naïve CD8+(+? +++)
CD4+/CD8+ TCM (+? +++)
CD4+/CD8+ TEM (+? +)
Treg
Cations, non-selective TRPM7 TRPM7 T cells  Mg2+ homeostasis [28]
Ca2+ CRAC ORAI1 T cells (+? +++)  Store-operated Ca2+ entry
 Gene expression
 IFNc, IL-2 production
 Immunological synapse
[26–29,44]
IP3R ITPR1-3 T cells  Store-operated Ca2+ entry
 Gene expression
[45,46]
Cl VRAC Unknown T cells (+? +)  Regulated volume decrease [47,48]
Na+ ASSC SCNN1 T cells (ENaCc)  Unknown [49,50]
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reticulum (ER) Ca2+ store, followed by STIM proteins that physi-
cally convey the signal from the ER to the plasma membrane, in-
duce the opening of CRAC channels and allow Ca2+ ions to enter
the cell [28]. Solely CRAC channels provide the prolonged Ca2+ in-
ﬂux into lymphocytes, but unfortunately in absence of a speciﬁc
CRAC channel blocker only little experimental data about the
in vivo function of these channels has been reported so far. How-
ever, a knock-in mutation of one CRAC encoding gene Orai1 causes
the expression of a non-functional ORAI1-R93W protein. The af-
fected mice show normal lymphocyte development, but T and B
cells display severely impaired store-operated Ca2+ entry and CRAC
channel function resulting in strongly reduced expression of sev-
eral key cytokines [29]. Moreover, genetic deletion of STIM1/2
ameliorates the disease course of EAE [30,31] and a human immu-
nodeﬁciency syndrome associated with deﬁciencies in STIM1 func-
tion was described recently [32].
In summary, T cell activity involves a complex interplay of dif-
ferent ionic currents that regulate basic T cell effector functions
like cytokine secretion and cell proliferation induced by T cell
receptor stimulation. The broad variety of different potassium
channels that are expressed on T cells point to a scenario in which
the function of potassium channel activity goes beyond the main-
tenance of the membrane potential. However, a potential contribu-
tion to intracellular signaling cascades is unknown so far (Table 1).
3. Ion channels on nerve cells
Classically, the central nervous system was considered an im-
mune-privileged organ. However, in case of neuroinﬂammatorydiseases like MS and EAE, nerve and immune cells get into contact.
Besides the inﬂuence of ionic conductances of immune cells,
numerous studies revealed that ion channels expressed on neurons
also contribute to the pathophysiological scenario during
neuroinﬂammation.
3.1. Voltage-gated sodium channels
Under healthy conditions, the voltage-gated sodium channel
Nav1.2 is expressed on immature, unmyelinated neurons. As such,
they support the continuous impulse transmission, but they are no
longer detectable on adult, myelinated neurons. The closely related
Nav1.6 channels support the saltatory conductance of the nerve
impulse at nodes of Ranvier of adult neurons. However, in case
of demyelination expression and distribution of voltage-gated so-
dium channels at neuronal somata and axons are completely al-
tered. Nav1.2 and Nav1.6 are found to be overexpressed at
demyelinated sites of the axonal membrane [51]. While Nav1.2
supports the restitution of the continuous form of signal conduc-
tance, Nav1.6 mediates a persistent sodium inward current that ﬁ-
nally induces the reversal of the Na+/Ca2+ exchanger of the
demyelinated membrane. The intracellular Ca2+ accumulation trig-
gers mitochondrial dysfunction and leads to neuronal cell death in
the end [51]. Based on these facts, the blockade of voltage-gated
sodium channels (especially Nav1.6) seems to be promising in
terms of a therapeutic target that might allow neuronal survival
and thus reduce permanent neurological deﬁcits of MS patients.
Inhibition of sodium channel function using speciﬁc blockers re-
vealed that two distinct blockers, phenytoin and carbamazepine,
signiﬁcantly improved the clinical course of the disease. However,
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nied by a signiﬁcantly increased inﬂammatory inﬁltrate within the
central nervous system and the death of nearly 60% of phenytoin-
treated and 8% of carbamazepine-treated EAE mice [52]. In a phase
2 trial, the neuroprotective role of lamotrigine, a partial sodium
channel blocker, was tested in patients with secondary progressive
multiple sclerosis (SPMS). The effect of lamotrigine on cerebral vol-
ume of SPMS patients was investigated by means of MRI, and it did
not differ from that of placebo over 24 months. However, lamotri-
gine seemed to cause early volume loss that reversed partially on
discontinuation of treatment [53]. Another clinical trial with phe-
nytoin in patients with primary progressive MS was planned, but
due to the clinical worsening after withdrawal in the animal study
mentioned above [52], the study was never initiated [54,55].
Although the ﬁndings in pre-clinical studies pointed to an effective
mechanism to ameliorate MS symptoms, sodium channel blockers
by now missed the clinical translation due to the rebound effect
after discontinuation of the drug.
3.2. Voltage-gated calcium channels
Several lines of evidence support the notion that aberrations in
ionic currents carried by voltage-gated calcium channels contrib-
ute to the pathophysiology in MS and EAE. Increased inﬂux of
extracellular calcium through voltage-gated calcium channels
(VGCC) was assumed to facilitate the neurological impairment
and pathological outcome in EAE, and by inference, MS. The
expression of the pore forming a1B-subunit of N-type calcium
channels (Cav2.2) was investigated in MS and EAE plaques and
was found to be overexpressed in active lesions [56]. By means
of electron microscopy, these a1B-subunits were found to be lo-
cated in the axonal membrane and thus might mediate an in-
creased neuronal calcium inﬂux. Based on these ﬁndings and
together with the fact that calcium channels are present on oligo-
dendrocytes [57] and axons [58] – both key targets in autoimmune
demyelination –, EAE mice were treated with two different calcium
channel blockers, bepridil and nitrendipine. Both drugs, although
different in many structural and functional respects, block calcium
inﬂux through L-type calcium channels (Cav1.2, Cav1.3, Cav1.4). As
compared to placebo-treated controls, these calcium antagonists
had comparable beneﬁcial effects with reduced inﬂammation and
axonal pathology on AT-EAE mice [59]. As largely increased intra-
cellular calcium levels are known to directly trigger apoptotic sig-
nals and neuronal degeneration, calcium channels also seem to
play a role in pathological mechanisms of inﬂammatory demyelin-
ating diseases. Nevertheless, there are no trials for clinical transla-
tion of calcium channel blockers so far.
3.3. Voltage-gated and K2P potassium channels
Intact electrical impulse transmission includes different potas-
sium conductances that are carried by voltage-gated and calcium-
activated potassium channels. At an intact, myelinated axon, the
voltage-gated potassium channels Kv1.1 and Kv1.2 are located
underneath the myelin sheath in the paranodes or internodal re-
gions. They affect the electrotonic conductance and repolarisation
of the action potential generated at the node by mediating K+ out-
ward currents [60]. Glia cells also possess inwardly rectifying
potassium channels (Kir4.1) that support the potassium homeosta-
sis in the extracellular space [7]. Demyelination induces alterations
in K+ channel expression and distribution, as there is an upregula-
tion of Kv1.1 and Kv1.2 on axons and of Kv1.4 on glia cells. Due to
increased K+ outward ﬂux from axons and a decreased K+ buffering
by glia cells, the extracellular K+ homeostasis is outbalanced and
postpones the K+ reversal potential to more positive values. As a
consequence, there is a gradual depolarization of the membranepotential which induces an inactivation of voltage-gated sodium
channels and hence signal conduction block. The axonal K+ outward
currents lead to an intracellular potassium depletion that is as-
sumed to be a ﬁrst step in apoptotic cascades as it triggers water
loss and disinhibition of intracellular proapoptotic enzymes [61].
Administration of a Kv1.1 selective blocker (BgK-F6A) ameliorates
disease course in EAE mice while it did not affect T cell activation
[62]. In vivo relevance of TASK channels on T lymphocytes was ad-
dressed by pre-treatment of myelin basic protein-speciﬁc encepha-
litogenic T lymphocytes with a TASK1 modulator (anandamide)
which was associated with signiﬁcant amelioration of the disease
course in Lewis rats [15]. AddingMOG-reactive T lymphocytes onto
acute living brain slices resulted in a signiﬁcantly higher number of
apoptotic neurons in wild-type slices compared with TASK1/
preparations [5]. Based on these recent ﬁndings about the contribu-
tion of TASK channels to EAE pathology, there is good evidence that
inhibition of TASK channels exerts an immunsuppressive as well as
a neuroprotective effect. Thus, these two pore domain K+ channels
could function as a new therapeutic concept in therapy of neuroin-
ﬂammatory disorders, but clinical trials are currently hampered by
the lack of available highly speciﬁc blockers.
Taken together, differently from clearly deﬁned channelopa-
thies like cystic ﬁbrosis, the MS pathology seems to be inﬂuenced
by multiple ion channels which include different ion selectivities
and which can be expressed both on neurons and on T lympho-
cytes. This indicates a highly complex scenario of MS pathogenesis
which should be taken into consideration while planning trials for
clinical translation of newly discovered therapeutic agents. Apart
from the postulated mechanism of action, there might be numer-
ous ‘‘off-target’’ effects in human beings, although convincing
pre-clinical studies in murine animal models and non-human pri-
mates have been performed in advance [1].
4. Differentiation between immune-suppressive/immune-
modulatory and neuroprotective drug actions
In MS, myelin and neurons are lost as a result of an inﬂamma-
tory attack on the central nervous system (CNS). The lesions alter
nerve conduction and contribute to disabling neurological deﬁcits
that vary with the location of demyelination plaques within the
CNS. Although the cause of MS remains undetermined, the pres-
ence of large immune inﬁltrates in the white matter of patients
suggests that myelin damage is immune-mediated. T and B lym-
phocytes are major components of these inﬁltrates whereas it is
accepted that autoimmune T cells mediate the early steps of new
multiple sclerosis lesions [63,64]. A number of experimental stud-
ies showed that the application of ion channel blockers to EAE ani-
mals induces attenuated disease courses and impaired clinical
severity as well as delayed onset of symptoms. However, in most
cases the exact mechanism of blocker action could not be eluci-
dated, since many of the blocked ion channels are expressed on
neuronal and immune cells as well as on the myelin-producing oli-
godendrocytes. A differentiation between the consequences of ion
channel modulation on neurons and on immune cells would be
beneﬁcial to get further insights into pathophysiological processes
and mechanisms of drug actions (Fig. 1).
4.1. ASIC1 – a neuroprotective Na+ channel
A sophisticated strategy to differentiate between an immune-
suppressive and neuroprotective drug effect can be a combination
of adoptive transfer-EAE with speciﬁc ion channel deﬁcient animal
models. Accordingly, Friese and colleagues used mice with a genet-
ically inactivated gene that encodes the neuronally expressed, pro-
ton-gated acid-sensing ion channel-1 (ASIC1) and compared them
with wild-type mice (C57BL/6). After immunization with MOG
Fig. 1. Ion channels on T cells and in the CNS which are involved in the pathophysiology of MS are depicted on the left side (T cells) and right side (myelinated and
demyelinated neurons). See text for an extensive description of the putative role of these channels. Abbreviations: ASIC, acid sensing ion channel; [Ca2+]I, intracellular calcium
concentration; CaM, Calmodulin; CaV, voltage-gated calcium channel; CRAC, Ca2+-release activated Ca2+ current; KCa, calcium-activated potassium channel; KV, voltage-gated
potassium channel; NaV, voltage-gated sodium channel; Na/Ca-Ex, sodium–calcium exchanger; TASK, TWIK-related acid-sensitive K+ channel.
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severity at disease maximum and an ensuing clinical deﬁcit. To
conﬁrm that the disease-modifying effect of inactivated ASIC1 is
T cell independent, effector T cells speciﬁc for MOG peptide and
isolated from wild-type and ASIC1 knockout mice were transferred
into naïve wild-type or ASIC1 knockout animals. Solely the disease
course of ASIC1 knockout mice, that received MOG-speciﬁc T cells
from wild-type or ASIC1 knockout donors, was ameliorated to an
equal degree in both cases. Thus, these authors were able to clearly
identify the blocked/ablated Na+ channel ASIC1 to facilitate neuro-
protection in AT-EAE animals, and they showed that this effect was
most likely neuron-dependent [6,65].
4.2. TASK1 modulates immune response and neurodegeneration
By applying an alternative approach, recent results from our lab
identiﬁed neuronally expressed TASK1 channels to exert a protec-
tive impact on neurons in EAE animals [5]. In TASK1 deﬁcient mice
(TASK1/), experimental autoimmune CNS inﬂammation was sig-
niﬁcantly attenuated and was accompanied by a markedly reduced
production of cytokines (IL2, IFNc) of type 1 T helper cells (Th1).
Absence of TASK1 did not affect immune subset distribution and
the phenotype of antigen-presenting cells, but it drastically im-
paired antigen-induced T cell proliferation and cytokine secretion.
Moreover, immunological detection of SMI32 positive axons in cer-
vical spinal cord sections revealed a beneﬁcial inﬂuence of TASK1
deletion on axonal degeneration under inﬂammatory conditions
in EAE mice. To directly show the positive effect being due to
TASK1 channels expressed on neurons, acute living brain slices
were incubated for 6 h with MOG-reactive CD4+ T lymphocytes.
A higher number of apoptotic neurons in wild-type slices com-
pared to TASK1/ preparations indicated a direct impact of TASK1
channels on neuronal survival and that the absence of TASK1 pro-
tected against immune-mediated axonal degeneration in EAE.
These results and other lines of evidence point to TASK1 channels
as being critical modulators of T cell immunity and neurodegener-
ation. Hypoxia and tissue acidiﬁcation, that are characteristic con-
ditions for an inﬂammatory environment as it occurs in EAE brainand in spinal cord tissue [6], modulate TASK1 channel function
[66–69]. Based on these results, on the unique pharmacological
proﬁle of TASK1 and on the knowledge about its extensive actions
on basic cellular processes, it is assumed that TASK1 channels on
neurons could push apoptotic mechanisms. An increased loss of
potassium ions is known to be a ﬁrst step in apoptosis which is fol-
lowed by a loss of intracellular water or can be directly coupled to
the activation of proapoptotic enzymes [70]. In agreement with
these ﬁndings, levels of a semi-selective TASK channel blocker,
the endocannabinoid anandamide, was shown to be elevated in
MS plaques [71]. This fact points to an endogenous strategy to sup-
port neuronal survival during MS attacks.
5. Conclusion
Currently approved drugs for multiple sclerosis have mostly
broad effects on the immune system (e.g., interferons, glatiramer
acetate, mitoxantrone). Newly emerging drugs follow the same
principle apart from their selective and deﬁned target structures
such as alpha4-integrin for natalizumab or sphingosin 1-phosphate
receptor for ﬁngolimod [72–75]. Ion channels have long been rec-
ognized as attractive target structures for other diseases as ligand-
gated and voltage-gated ion channels can both be found among the
top ﬁve pharmaceutical target groups of FDA-approved agents
[76]. A diverse selection of ion channels from different protein fam-
ilies (e.g., voltage-gated Na+-/K+-/Ca2+ channels, epithelial Na+-/K+
channels and TRP channels [77]) provides further evidence that
ion channels per se should be regarded as putative promising
new targets for MS. This is especially the case for MS subtypes with
a strong degenerative component (primary progressive and sec-
ondary progressive MS) with a strong need for novel therapies.
However, the clinical translation of ion channel modulation re-
mains a major challenge for MS. So far, only few larger clinical tri-
als (e.g., lamotrigine) have been performed and most approaches
are still in an early preclinical stage. Common reasons for this delay
are a lack of highly speciﬁc ion channel inhibitors on one side
(as for example for the family of K2P channels) and a lack of knowl-
edge about the exact role of ion channels in the context of
P. Ehling et al. / FEBS Letters 585 (2011) 3836–3842 3841autoimmunity as can be seen in case of the phenytoin/carbamaze-
pin withdrawal side effects.
A major advantage of pharmacological targeting of ion channels
in autoimmune degeneration is their ubiquitous expression on all
cells with very heterogeneous functions. Therefore, a speciﬁc selec-
tion of the appropriate ion channel could inﬂuence various aspects
of multiple sclerosis. Blockade of KV1.3 has been postulated as a
potential immunosuppressive strategy for MS [21,22,78]. However,
clinical results are still pending and a number of questions remains
open (e.g., expression of KV1.3 on other cell types, crossreaction of
channel blockers with closely related KV1.x subtypes or long-term
effect of KV1.3 blockade). Blockade of TASK channels on T cells
might prove beneﬁcial as well, however, the pharmacological
development of speciﬁc K2P blockers is still unsatisfactory. As the
family of K2P channels has been discovered only 15 years ago, fur-
ther development can be expected in this direction.
Another important target of ion channel modulation is the pre-
vention of neuronal cell death and neurodegeneration. A clinical
trial using amiloride as an unspeciﬁc ASIC1 blocker was announced
in Oxford and a number of other promising targets (TASK1, NaV1.2/
6) have not been addressed in clinical trials yet. As recent research
for MS has repetitively emphasized the importance of early and
ongoing neurodegeneration – partly independent from inﬂamma-
tion – in MS, the therapeutical impact of addressing ion channels
which directly inﬂuence neurodegeneration might be very attrac-
tive. It can be expected that a number of clinical trials will be
started in the next years which will hopefully not only expand
our knowledge about ion channel physiology but also lead to
new treatment strategies for autoimmune diseases.
The identiﬁcation of ion channels as new target structures in MS
may also facilitate the search for genetic alterations or polymor-
phisms of the underlying genes that lead to disease generation.
This may help to establish genetic testing for MS susceptibility
and choosing effective drugs for treatment.
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